NCT06091423招募中2 期
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study ( FISSION Study )
Xiaofeng Chen1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2023年10月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
Gastric cancer is the third leading cause of morbidity and mortality among malignant tumors in China, and less than 30% of patients can be cured by surgery. Liver metastasis, retroperitoneal lymph node metastasis and peritoneal metastasis are the most common metastatic sites of gastric cancer, which are also the important causes of death. Improve the conversion of oligonucleotides transfer patients resection rate, prolonged progression-free survival of these patients, is an important direction to improve survival of patients with advanced gastric cancer;
This study was a prospective, single-arm, multi-center clinical study. We plan to treat patients with gastric cancer/gastroesophageal junction adenocarcinoma with liver and/or retroperitoneal lymph node metastasis only with XELOX regimen + fruquinitinib + sintilimab for 4-6 cycles before surgery/ablation conversion therapy to achieve tumor-free status as far as possible. To explore the value of conversion therapy in patients with intrahepatic oligometastasis of gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18-75 years of age;
- •Understand the steps and content, and written informed consent signed voluntarily;
- •Is confirmed by histopathology and/or cytology her2-negative or HER2 status unknown late recurrence or stomach esophagus stomach/integration of adenocarcinoma;
- •In this research to define transfer of oligonucleotides definition: the primary lesion and regional lymph node metastasis of process to determine the surgeon can be cut or boundary can be cut, only intrahepatic metastasis and distant metastasis (metastases number 5 or less, a single lesion or less 5 cm in diameter.) And or retroperitoneal lymph node metastasis (16a2,16b1,16a1,16b2 metastasis), no other distant metastasis;
- •At least one measurable lesion according to RECIST 1.1 criteria;
- •No previous treatment with VEGFR-targeted drugs and PD-1/PD-L1 monoclonal antibodies. Patients who had relapsed more than 6 months after the completion of postoperative adjuvant chemotherapy with platinum or paclitaxel or fluorouracil and had no grade 2 or higher toxicity were eligible for enrollment.
- •ECOG PS score: 0-1;
- •Expected survival time ≥3 months;
- •The main viscera function is good, namely into groups of related within 14 days before check index meet the following requirements:
- •(1) hemoglobin ≥80 g/L; (2) neutrophil count >1.5×109/L; (3) platelet count ≥80×109/L; (4) Total bilirubin ≤2.5×ULN (upper limit of normal); (5) serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5×ULN; (6) the endogenous creatinine clearance or 60 ml/min (Cockcroft - Gault formula); (7) Echocardiography: left ventricular ejection fraction (LVEF)≥50%; (8) Thyroid function indexes: thyroid stimulating hormone (TSH) and free thyroxine (FT3/FT4) were in the normal range or only mildly abnormal, without related clinical symptoms; (9) A body weight of 40 kg or more, or a BMI > 18.5;
排除标准
- •Patients with other malignant tumors in the past or at the same time, but have been cured of early tumors, including basal cell carcinoma of the skin and carcinoma in situ of the cervix, stage I lung cancer, stage I colorectal cancer and other tumors that do not affect the patient's life in the short term according to the investigator's judgment can be excluded;
- •Participated in other drug clinical trials within four weeks;
- •Multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
- •Patients with a history of bleeding and any bleeding events of CTCAE5.0 grade 3 or higher within 4 weeks before screening;
- •Metastasis in other distant sites, including but not limited to lung metastasis, brain metastasis, bone metastasis, distant lymph node metastasis, and peritoneal metastasis;
- •Patients with hypertension not well controlled by single antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); Patients with a history of unstable angina; Newly diagnosed angina pectoris within 3 months before screening or myocardial infarction within 6 months before screening; Arrhythmias (including QTcF ≥450 ms in men and ≥470 ms in women) required long-term use of antiarrhythmic drugs and New York Heart Association (NYHA) grade ≥II cardiac dysfunction;
- •Long-term unhealed wounds or incompletely healed fractures;
- •Imaging shows that the tumor has invaded the important blood vessels or the investigator judges that the patient's tumor has a high possibility of invading the important blood vessels during the treatment and causing fatal hemorrhage;
- •Abnormal coagulation function, with bleeding tendency (14 days before enrollment must meet: INR in the normal range without anticoagulant or clinically insignificant abnormality); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogues; International standardization in prothrombin time ratio (INR) under the premise of 1.5 or less, allowing purpose to prevent the use of low-dose warfarin (1 mg orally, once per day) or low-dose aspirin (amount does not exceed 100 mg daily);
- •Occurrence of arterial/venous thrombosis events within 6 months before screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (except for venous thrombosis caused by venous catheterization due to previous chemotherapy and judged by investigators to be cured), and pulmonary embolism;
- •Urine routine showed urine protein ≥++ and confirmed 24-hour urine protein quantitation >1.0 g;
- •Previous use of immune-targeted therapy drugs;
- •Have a history of immunodeficiency or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
- •Patients with infectious pneumonia, non-infectious pneumonia, interstitial pneumonia and other patients requiring corticosteroids;
- •A history of severe chronic autoimmune diseases, such as systemic lupus erythematosus; He had a history of inflammatory bowel disease such as ulcerative enteritis, Crohn's disease, and a history of chronic diarrhea such as irritable bowel syndrome. A history of sarcoidosis or tuberculosis; Patients with a history of active hepatitis B or C, and HIV infection; Good control of severe autoimmune disease, such as dermatitis, arthritis, psoriasis, etc can be into the group. Patients with hepatitis B virus titer <1000copy/ml were eligible for enrollment.
- •Patients with hypersensitivity to human or murine monoclonal antibodies;
- •Have a history of psychotropic drug abuse and cannot quit or have mental disorders;
- •Patients who do not follow the doctor's advice, do not follow the prescribed medication, or have incomplete data, which may affect the efficacy or safety judgment;
- •Concomitant diseases that, in the judgment of the investigator, seriously compromise patient safety or interfere with patient completion of the study.
研究组 & 干预措施
Experimental
Experimental
XELOX combined with Fruquintinib and Sintilimab
干预措施: XELOX combined with Fruquintinib and Sintilimab (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year]
Time from randomization to disease progression or death from any cause
次要结局
- Duration of Response (DOR)(from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year)
- Objective response rate (ORR)(Time Frame: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year)
- translational rate(2-3 months)
- Overall survival (OS）(from randomization until death due to any cause, assessed up to 3 year)
- Disease Control Rate (DCR)(from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year)
- Adverse event (AEs)(2 years)
研究者
Xiaofeng Chen
professor
The First Affiliated Hospital with Nanjing Medical University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric CancerGastric Cancer Stage IIGastric Cancer Stage IIINCT04119622Aiping Zhou30
终止
2 期
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction CarcinomaGastric CarcinomaGastroesophageal Junction CarcinomaNCT00256321University of California, Irvine4
终止
3 期
Xeloda Maintenance Versus BSC in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02060669Samsung Medical Center10
Unknown
2 期
Study on Neoadjuvant Chemotherapy for Advanced Gastric CancerAdvanced Gastric CarcinomaNCT02163291Peking University30
招募中
2 期
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)Rectal CancerNCT06770270Second Affiliated Hospital, School of Medicine, Zhejiang University68